NASDAQ: UPBUpstream Bio Inc Stock
$9.61+0.55 (+6.07%)
Updated Mar 14, 2025
UPB Price
$9.61
Fair Value Price
N/A
Market Cap
$515.49M
52 Week Low
$6.65
52 Week High
$29.46
P/E
-1.72x
P/B
1.1x
P/S
94.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.37M
Earnings
-$62.81M
Gross Margin
100%
Operating Margin
-2,650.04%
Profit Margin
-3,223.4%
Debt to Equity
0.03
Operating Cash Flow
-$59M
Beta
2.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UPB Overview
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UPB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
UPB
Ranked#151 of 484
Ranked#151 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.84 | A | |
| $137.96 | A | |
| $8.16 | A |
Be the first to know about important UPB news, forecast changes, insider trades & much more!
UPB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UPB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UPB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
UPB is good value based on its book value relative to its share price (1.1x), compared to the US Biotechnology industry average (4.68x)
P/B vs Industry Valuation
UPB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more UPB due diligence checks available for Premium users.
Valuation
UPB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.72x
Industry
-118.09x
Market
3,446.61x
UPB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.1x
Industry
4.68x
UPB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UPB's financial health
Profit margin
Revenue
$613.0k
Net Income
-$21.2M
Profit Margin
-3,554.6%
UPB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
UPB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$481.7M
Liabilities
$11.9M
Debt to equity
0.03
UPB's short-term assets ($479.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UPB's short-term assets ($479.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UPB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.6M
Investing
$41.9M
Financing
$270.6M
UPB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UPB vs Biotech Stocks
Upstream Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.